ImmunityBio is continuously pursuing new immunotherapies designed to attack disease by enhancing the patient’s immune system, not weakening it. Learn more about our research: https://lnkd.in/g42xvnBG
关于我们
ImmunityBio, Inc. (formerly NantKwest, Inc.) is developing cell and immunotherapy products that are designed to help strengthen each patient’s natural immune system, potentially enabling it to outsmart the disease and eliminate cancerous or infected cells. The activation of the innate immune system is key to the development of immunological memory. Over the last two decades, our founder and Executive Chairman Dr. Patrick Soon-Shiong has investigated mechanisms to activate the immune system to attack tumors that can otherwise evade and escape the body’s defense mechanisms. After inventing the world’s first protein nanoparticle drug, Abraxane, Dr. Soon-Shiong turned his focus to the next generation of immunotherapies. ImmunityBio was founded in 2014 to create innovative immunotherapies that address serious unmet needs in oncology and infectious diseases. "At ImmunityBio, we envision a day when we no longer fear cancer but are able to conquer it, thanks to the biological wonder that is the human immune system. Our scientists are working to develop remarkable new therapies that harness that inherent power by amplifying both branches of the immune system, attacking cancerous or infected cells today while building immunological memory for tomorrow. The goal: to reprogram the patient’s immune system and treat the host rather than just the disease." -Dr. Patrick Soon-Shiong, Executive Chairman
- 网站
-
https://www.ImmunityBio.com
ImmunityBio, Inc.的外部链接
- 所属行业
- 生物技术研究
- 规模
- 501-1,000 人
- 总部
- San Diego，CA
- 类型
- 上市公司
- 领域
- Immunotherapy、Cancer、Infectious Diseases、Natural Killer、T Cell、Vaccines、Oncology、Vaccine、Fusion Proteins、Clinical Trials、Manufacturing、COVID-19、Yeast和Cell Therapy
地点
ImmunityBio, Inc.员工
动态
-
Glioblastomas are the most prevalent and aggressive malignant brain tumors, with a 40% survival rate in the first year after diagnosis. Learn about our efforts to find (or develop) better treatments for these patients: https://lnkd.in/gm8a_Bfh
-
ImmunityBio is developing investigational immunotherapy products designed to help treat and prevent cancers resulting from Lynch syndrome. Read more here: https://lnkd.in/djjBtnwV
-
We focus on advancing cancer research so we can deliver a better quality of life to those affected by cancer. Learn more about our “triangle offense” approach that takes advantage of the natural immune system’s power: https://lnkd.in/gDNTqiZD
-
Today is #NHAAD, a day we address the impact of #HIV and #AIDS in adults over 50. ImmunityBio is exploring how we can enable our own immune system to manage HIV and potentially eliminate the need for antiretroviral therapy. Learn more: https://lnkd.in/giKVJDrS
-